1.64 USD
↗ 0.13 (8.61%)AT CLOSE (11:59 AM EDT)
Neumora Therapeutics, Inc. Common Stock
NMRANASDAQ • USD
1.59
↘ 0.05 (3.05%)
POST MARKET (AS OF 07:13 PM EDT)
Post Market
AS OF 07:13 PM EDT
1.59
↘ 0.05 (3.05%)
Market: CLOSED
Neumora Therapeutics, Inc. Common Stock (NMRA) trades at $1.64 per share. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On valuation, NMRA trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Jun 26, 2026.
Open?$1.50
High?$1.66
Low?$1.48
Prev. Close?$1.51
Volume?15.0M
Avg. Volume?3.2M
VWAP?$1.59
Rel. Volume?4.70x
Bid / Ask
Bid?$1.30 × 100
Ask?$1.84 × 100
Spread?$0.54
Midpoint?$1.57
Valuation & Ratios
Market Cap?303.9M
Shares Out?185.3M
Float?68.9M
Float %?41.2%
P/E Ratio?N/A
P/B Ratio?4.30
EPS?-$1.20
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Employees
92
Market Cap
279.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2023-09-15
Address
260 ARSENAL PLACE, SUITE 1
WATERTOWN, MA 02472
Phone: (857) 760-0900
WATERTOWN, MA 02472
Phone: (857) 760-0900
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?51
Piotroski F-Score?0/9Weak
Altman Z-Score?-12.89Distress
Confidence?55%Low
Short InterestElevated
Short % of Float?7.14%Elevated
Short Interest?4.9M
Days to Cover?2.2
Free Float68.9M
Avg Daily Volume2.3M
Settlement Date2026-06-15
Financial Health
Current Ratio?5.09Strong
Quick Ratio?5.09Strong
Cash Ratio?4.88Strong
Debt/Equity?0.75Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?4.30FAIR▾
Peers100
S&P42
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-1.0CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-314.7%WEAK▾
S&P3
ROA?-144.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-193412000
Enterprise Value?$209.8M
Fundamentals ratios updated end of day